LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same
DC Berwick, GR Heaton, S Azeggagh… - Molecular …, 2019 - Springer
Since the discovery of leucine-rich repeat kinase 2 (LRRK2) as a protein that is likely central
to the aetiology of Parkinson's disease, a considerable amount of work has gone into …
to the aetiology of Parkinson's disease, a considerable amount of work has gone into …
Promising drug targets and associated therapeutic interventions in Parkinson's disease
SN Rai, P Singh, R Varshney… - Neural regeneration …, 2021 - journals.lww.com
Parkinson's disease (PD) is one of the most debilitating brain diseases. Despite the
availability of symptomatic treatments, response towards the health of PD patients remains …
availability of symptomatic treatments, response towards the health of PD patients remains …
Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice
Mutations in the LRRK2 gene represent the most common genetic cause of late onset
Parkinson's disease. The physiological and pathological roles of LRRK2 are yet to be fully …
Parkinson's disease. The physiological and pathological roles of LRRK2 are yet to be fully …
Reduced synaptic activity and dysregulated extracellular matrix pathways in midbrain neurons from Parkinson's disease patients
Several mutations that cause Parkinson's disease (PD) have been identified over the past
decade. These account for 15–25% of PD cases; the rest of the cases are considered …
decade. These account for 15–25% of PD cases; the rest of the cases are considered …
Parkinson's disease: convergence on synaptic homeostasis
SF Soukup, R Vanhauwaert, P Verstreken - The EMBO journal, 2018 - embopress.org
Parkinson's disease, the second most common neurodegenerative disorder, affects millions
of people globally. There is no cure, and its prevalence will double by 2030. In recent years …
of people globally. There is no cure, and its prevalence will double by 2030. In recent years …
α-Synuclein–regulator of exocytosis, endocytosis, or both?
α-Synuclein is known as a presynaptic protein that binds to small synaptic vesicles. Recent
studies suggest that α-synuclein is not only attracted to these tiny and therewith highly …
studies suggest that α-synuclein is not only attracted to these tiny and therewith highly …
Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease
Members of the synaptic vesicle glycoprotein 2 (SV2) family of proteins are involved in
synaptic function throughout the brain. The ubiquitously expressed SV2A has been widely …
synaptic function throughout the brain. The ubiquitously expressed SV2A has been widely …
Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease
Dopamine was first identified as a neurotransmitter localized to the midbrain over 50 years
ago. The dopamine transporter (DAT; SLC 6A3) and the vesicular monoamine transporter 2 …
ago. The dopamine transporter (DAT; SLC 6A3) and the vesicular monoamine transporter 2 …
Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells
I Russo, G Berti, N Plotegher, G Bernardo… - Journal of …, 2015 - Springer
Background Over-activated microglia and chronic neuroinflammation contribute to
dopaminergic neuron degeneration and progression of Parkinson's disease (PD). Leucine …
dopaminergic neuron degeneration and progression of Parkinson's disease (PD). Leucine …
The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease
J Schapansky, JD Nardozzi, MJ LaVoie - Neuroscience, 2015 - Elsevier
The proteins alpha-synuclein (αSyn) and leucine rich repeat kinase 2 (LRRK2) are both key
players in the pathogenesis of the neurodegenerative disorder Parkinson's disease (PD) …
players in the pathogenesis of the neurodegenerative disorder Parkinson's disease (PD) …